Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy

Despite several therapeutic advances, patients with multiple myeloma (MM) require additional treatment options since no curative therapy exists yet. In search of a novel therapeutic antibody, we previously applied phage display with myeloma cell screening and developed TP15, a single-chain fragment...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Klausz, Katja, Cieker, Michael, Kellner, Christian, Rösner, Thies, Otte, Anna, Krohn, Steffen, Lux, Anja, Nimmerjahn, Falk, Valerius, Thomas, Gramatzki, Martin, Peipp, Matthias
Format: Artigo
Idioma:Inglês
Publicat: Fondazione Ferrata Storti 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252953/
https://ncbi.nlm.nih.gov/pubmed/32499243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2020.251371
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars